title: Do drug elution components increase the risk of fracture of sirolimus-eluting stents?
abstract: OBJECTIVE
  Stent fracture (SF) of sirolimus-eluting stents (SES) has emerged recently in the literature and shown to be associated with an increased risk of restenosis; however, little is known regarding SF after bare-metal stent implantation. We sought to assess whether the use of SES was associated with an increased risk of SF compared with its bare-metal platform, the Bx-velocity stent (BX-BMS).
  
  
  METHODS
  A total of 478 lesions in 416 patients undergoing SES implantation and subsequent angiography 6-9 months after the index procedure were compared with 152 lesions in 142 consecutive patients treated with BX-BMS. Stented lesions with total stent-length greater than 40 mm were excluded.
  
  
  RESULTS
  There were no significant differences in overall baseline clinical and anatomic features between the SES and BX-BMS groups, or in SF frequencies at 6-9 month follow-up (4.4% for SES and 1.3% for BX-BMS, P= 0.078). In-stent restenosis was observed more often in SF lesions versus non-SF lesions (34.8 vs. 7.7%, P< 0.001) in association with a higher 3-year adverse events rate (27.3 vs. 13.6%, P = 0.076). The risk of SF at 6-9 months was independently associated with total stent length [odds ratio (OR), 2.13; 95% confidence interval (CI), 1.18-3.83; P = 0.012], angulated lesions (OR, 4.25; 95% CI, 1.80-10.00; P = 0.001), and right coronary artery lesions (OR, 3.55; 95% CI, 1.46-8.62; P = 0.005) but not with SES use.
  
  
  CONCLUSIONS
  Stent implantation in right coronary artery lesions, tortuous lesions, and/or longer lesions covered with longer stents, and not SES versus BX-BMS use, may be associated with increased likelihood of SF.
authors.affiliation: Department of Cardiology, Fujita Health University Hospital, Toyoake, Kutsukake, Toyoake, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kawai
authors.forename: Hisashi
authors.initials: H
authors.lastname: Umeda
authors.forename: Masaya
authors.initials: M
authors.lastname: Ota
authors.forename: Kousuke
authors.initials: K
authors.lastname: Hattori
authors.forename: Makoto
authors.initials: M
authors.lastname: Ishikawa
authors.forename: Masanori
authors.initials: M
authors.lastname: Okumura
authors.forename: Shino
authors.initials: S
authors.lastname: Kan
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nakano
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Naruse
authors.forename: Shigeru
authors.initials: S
authors.lastname: Matsui
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishii
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hishida
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ozaki
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008670:Metals; D008875:Middle Aged; D016017:Odds Ratio; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D002317:Cardiovascular Agents; D008670:Metals; D020123:Sirolimus